Navigation Links
European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™
Date:2/17/2012

mail alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Pixuvri in particular, including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that Pixuvri may not be the first drug approved as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive NHL, that a conditional marketing authorization for Pixuvri may not be granted by the European Commission within the next few months or at all, that CTI may not be able to complete the PIX306 clinical trial of Pixuvri-rituximab versus gemcitabine-rituximab in patients with aggressive B-cell NHL, who failed front-line CHOP-R and who are not eligible for ASCT (2nd line) or failed ASCT (3rd or 4th line) by June 2015 or at all as required by the EMA or have the results of such trial available by June 2015 or at all, that CTI may not be able complete a post-marketing study aimed at confirming the clinical benefit observed in the PIX 301 trial, that full marketing authorization for Pixuvri may not be obtained, that the EMA and/or the European Commission may not formally adopt the CHMP's recommendation regarding Pixuvri, that Pixuvri may not be approved for marketing in all of the E.U. Member States and the European Economic Area members, that the EMA may request addit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
2. Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
3. European Pharmaceutical and Biotech Contract Manufacturing Markets
4. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
5. ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa
6. Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
7. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
8. Dehaier Medical Enters European Homecare Medical Product Market
9. Successful ILM-Blue Patent Opposition Proceedings Before the European Patent Office; Patent Validity Confirmed
10. No European Scientists Left by 2020?
11. US and European Bariatric (Obesity) Surgical Devices Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... Board of Directors has authorized the implementation of a 1:25 ... be completed on or before January 15, 2012. ... by the Company,s stockholders at a November 4, 2011, special ...
... EXTON, Pa., Jan. 3, 2012 ViroPharma Incorporated (Nasdaq: ... Julie H. McHugh to its board of directors. ... health care industry experience and leadership to ViroPharma,s Board ... of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  ...
Cached Medicine Technology:Radient Pharmaceuticals Announces Reverse Stock Split 2ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors 2
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... , ... LLP (ENTA) announced today that it has expanded the implementation of its state-of-the-art Electronic Medical ... City, Long Island, Westchester, Rockland, Putnam and Orange Counties and northern New Jersey. All of ... ...
... ... Department of Corrections , ... Miami, FL (PRWEB) July 1, 2010 -- JPay.com, the Trusted Leader in ... million offenders nationwide with absolutely no cost to correctional departments and today announced the ...
... ... the release of their new Alpha 3C™ formula, designed to naturally support focus, ... ... provider of premium dietary supplements, announces the release of their new Alpha 3C™ ...
... that older adults commonly have low vitamin D levels and ... the metabolic syndrome, a condition that affects one in four ... Annual Meeting in San Diego. "Because the metabolic syndrome ... vitamin D level in the body might be important in ...
... men with higher testosterone levels are more likely to ... the future. The results were presented at The Endocrine ... study finding contradicts smaller studies that have shown that ... cardiovascular disease," said presenting author Kristen Sueoka, MD, a ...
... ... Marijuana emerges as the most popular plant in the United States we,re still ... Casias is a perfect example of the discrimination as at the young age ... been forced to fight Wal-Mart after losing his job for using medicinal marijuana ...
Cached Medicine News:Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 3Health News:JPay, the Apple of Washington State DOC's eye 2Health News:Purity Products Releases Alpha 3C 2Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Higher testosterone may raise risk of heart disease in elderly men 2Health News:Fired Wal-Mart Employee Accepts Full Scholarship to The Medical Marijuana Academy 2
... O.R. Special Protective Apron is made ... and a sterile gown. Uniquely it ... sterile field. Reaching through the back ... are released, and the protective apron ...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... coat apron, weight is distributed uniformly ... comfortable wear without fatigue. Made to ... front closing special procedure apron comes ... that make it a cinch to ...
... Wolfs Easy Wrap Apron has always ... easy to put-on, adjust and take-off. Our ... new Easy sures Wrap features two velcro ... The attached Thyroid collar adjusted to fully ...
Medicine Products: